Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Long-term exposure to air pollution (PM2.5) raises risk of developing cancer by 11 % and of dying from cancer by 12 %

The Union for International Cancer Control (UICC), with support from the Clean Air Fund, has released a global report, Clean air in cancer control: An overview of the evidence, presenting data on the scale of cancer risk and mortality from polluted air.

21 Apr 2026

New roadmap links liver cancer biology to immunotherapy and precision medicine

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide.

17 Apr 2026

Study explains the link between NDMA-contaminated water and childhood cancer

A new study from MIT suggests that a carcinogen that has been found in medications and in drinking water contaminated by chemical plants may have a much more severe impact on children than adults.

17 Apr 2026

Gut-liver changes drive foodborne infection severity in fatty liver disease

A research team led by the University of California, Irvine's Joe C. Wen School of Population & Public Health has uncovered a critical biological link explaining why individuals with metabolic dysfunction–associated steatotic liver disease (MASLD), or fatty liver disease, face significantly worse outcomes from certain foodborne infections.

15 Apr 2026

Liver cancer burden rising globally amid shift to metabolic risks

Primary liver cancer continues to pose a major global health challenge, ranking as the third leading cause of cancer-related deaths worldwide.

15 Apr 2026

Gaining weight before age 30 tied to higher mortality

The study reveals that weight gain before 30 years is associated with increased mortality risk, underscoring the need for early obesity intervention strategies.

15 Apr 2026

Hepatologists effectively deliver palliative care to patients with liver disease

Advanced liver disease (ALD) occurs when significant scarring causes the liver to lose function. Patients with ALD often have serious health challenges but have limited access to palliative care that could improve their quality of life.

13 Apr 2026

Pseudogene lncRNAs regulate cancer stem cell behavior and signaling

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy due to their innate capacity for self-renewal and differentiation.

11 Apr 2026

New blood test spots four cancers and other diseases by stripping away healthy DNA noise

MethylScan is a new low-cost cell-free DNA methylome test that removes much of the healthy blood DNA background, helping rare disease signals stand out more clearly. In more than 1,000 people, it showed strong performance for detecting four cancers, classifying liver diseases, and identifying organ-specific damage.

7 Apr 2026

Gene signature maps cholangiocarcinoma subtypes for precision treatment

Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly concealed and heterogeneous nature.

31 Mar 2026

New genetic ‘roadmap’ advances precision therapy for intrahepatic cholangiocarcinoma

The 1,341-gene signature for intrahepatic cholangiocarcinoma offers a framework for precise diagnosis and tailored therapies, addressing tumor heterogeneity.

From BGI Genomics 31 Mar 2026

Machine learning model predicts liver cancer risk with high accuracy

A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high accuracy.

26 Mar 2026

Survey: Public awareness of alcohol-related cancer risk remains unchanged

Public awareness of the link between drinking alcohol and elevated cancer risk remains unchanged since February 2025, with over half of Americans saying that regularly consuming alcohol increases your chances of later developing cancer, according to a new survey by the Annenberg Public Policy Center (APPC) of the University of Pennsylvania.

19 Mar 2026

Tiny gene mutations shape cancer behavior and immune response

Cancer is often thought of as a single disease. Yet even tumors that arise in the same organ can follow very different genetic paths.

19 Mar 2026

New insight into origins of rare liver tumors in children

Liver cancer in children is rare, but when it occurs the two main types are hepatoblastoma (HB) and hepatocellular carcinoma (HCC).

16 Mar 2026

Boron neutron capture therapy shows promise for deadly brain tumors

Malignant gliomas are among the deadliest brain cancers, with limited treatment options and poor survival.

9 Mar 2026

Women face higher liver fibrosis risk from cardiometabolic factors than men

Women with certain cardiometabolic risk factors, including type 2 diabetes and high waist circumference, face a greater increase in risk for liver fibrosis than men with the same risk factors.

9 Mar 2026

New fragmentome technology can detect early liver fibrosis and cirrhosis

Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence (AI)-based liquid biopsy test using genome-wide cell-free DNA (cfDNA) fragmentation patterns and repeat landscapes can detect early liver fibrosis and cirrhosis, and may also reveal signals of broader chronic disease burden.

4 Mar 2026

Alcohol abstinence can lead to regression of existing liver-related complications

Consistent and permanent abstinence from alcohol can lead to the regression of existing liver-related complications, even in cases of advanced alcohol-related cirrhosis.

4 Mar 2026

Mursla Bio accelerates US commercial deployment of EvoLiver through ABHI program

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve chronic disease outcomes for at-risk patients, today announced it has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator.

4 Mar 2026